A Study of Second-line Treatment With Apatinib in Patients With Advanced Intrahepatic Cholangiocarcinoma
Status:
Completed
Trial end date:
2019-05-08
Target enrollment:
Participant gender:
Summary
The purpose of this study is to explore the efficacy and safety of second-line treatment of
apatinib in advanced intrahepatic cholangiocarcinoma patients and evaluate drug safety,
progression free and overall survival. The primary endpoint of this study is objective
response rate (ORR), disease control rate (DCR) and progression-free survival (PFS).